Trinity Technologies reintroducing generic drugs
Executive Summary
The Roseville, Michigan-based firm will have six generic drug products re-entering the market by January. The company voluntarily suspended manufacturing and distribution in August 1993 to address compliance problems, mainly related to process validation ("The Pink Sheet" Aug. 16, 1993, T&G-14). Trinity received additional capital for state-of-the-art manufacturing and processing equipment when it was acquired in March by Therapharm Holdings, Inc. Trinity expects to file several ANDAs in 1995 for long acting and narrow therapeutic range drugs